Literature DB >> 514940

Adverse reaction to disopyramide.

J B Dibble, N R Webster.   

Abstract

A case is reported where the use of i.v. disopyramide for a supraventricular tachycardia resulted in a more serious ventricular dysrhythmia giving hypotension and this probably contributed to the development of a myocardial infarction. Attention is drawn to the possible risk.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 514940      PMCID： PMC2428081          DOI： 10.1136/pgmj.55.646.570

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  7 in total

1.  Clinical evaluation of a new anti-arrhythmic agent, SC-7031.

Authors:  M J KATZ; C E MEYER; A EL-ETR; S J SLODKI
Journal:  Curr Ther Res Clin Exp       Date:  1963-07

2.  The effects of disopyramide on the human heart: an electrophysiological study.

Authors:  R A Spurrell
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

3.  Acute termination of cardiac arrhythmias with intravenous disopyramide.

Authors:  H F Mizgala; P R Huvelle
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

4.  The use of disopyramide in the treatment of arrhythmias in ambulatory patients.

Authors:  M B Jones
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

5.  Pharmacology of a new antiarrhythmic agent, gamma-diisopropyl-amino-alpha-phenyl-alpha-(2-pyridyl)-butyramide (SC-7031).

Authors:  C M MOKLER; C G VAN ARMAN
Journal:  J Pharmacol Exp Ther       Date:  1962-04       Impact factor: 4.030

6.  Increase of ventricular extrasystoles after disopyramide.

Authors:  M Härkönen
Journal:  Lancet       Date:  1978-04-01       Impact factor: 79.321

7.  Oral disopyramide for the prevention of arrhythmias in patients with acute myocardial infarction admitted to open wards.

Authors:  N Zainal; D J Carmichael; J W Griffiths; E M Besterman; P H Kidner; A D Gillham; G D Summers
Journal:  Lancet       Date:  1977-10-29       Impact factor: 79.321
  7 in total
  3 in total

Review 1.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

Review 2.  QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards.

Authors:  M Zehender; S Hohnloser; H Just
Journal:  Cardiovasc Drugs Ther       Date:  1991-04       Impact factor: 3.727

Review 3.  Drug-induced torsade de pointes. Incidence, management and prevention.

Authors:  T S Faber; M Zehender; H Just
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.